SAN DIEGO, June 22 /PRNewswire/ -- CetylMax, LLC and Flexadren, LLC, manufacturers and distributors of tablet form and topical Cetylated Fatty Acids (CFA's) products aiding in joint support and pain relief, announced today that Imagenetix (OTC Bulletin Board: IAGX), the manufacturer of Celadrin, did not prevail in its claims against CetylMax(R) and Flexadren(R), and misrepresented the nature and outcome of the Federal litigation between CetylMax(R) and Flexadren(R) and Imagenetix.
Imagenetix filed a Federal lawsuit against CetylMax(R) and Flexadren(R) on July 29, 2008 ("the Imagenetix lawsuit"), in the United States District Court for the Southern District of California. The Imagenetix lawsuit claimed that CetylMax(R) and Flexadren(R) had affronted the Lanham Act and California Business and Professions Code. CetylMax(R) and Flexadren(R) vehemently denied the Imagenetix lawsuit assertions, and immediately filed their own counterclaim lawsuit against Imagenetix ("the CetylMax/Flexadren lawsuit") in the same court.
On October 27, 2008, the parties appeared before the Honorable Judge William McCurine, Jr., for an Early Neutral Evaluation Conference (ENE). At that conference the parties mutually settled all of their respective claims, raised in both the Imagenetix lawsuit and the CetylMax/Flexadren lawsuit. The sole issue left for the Court to decide was whether any attorneys' fees should be awarded.
Following briefing by the parties' attorneys, on February 2, 2009, Judge McCurine ruled that Imagenetix was not entitled to any attorneys' fees. The Court concluded that Imagenetix had not succeeded on any of its claims against CetylMax(R) or Flexadren(R), and was thus not the prevailing party. Judge McCurine's decision cleared CetylMax(R) and Flexadren(R) of any bad faith or malice.
Roger LeFevre, Chief Executive Officer of CetylMax and Flexadren, commented, "both CetylMax(R) and Flexadren(R) have been completely exonerated of all Imagenetix's claims, and we're very happy with the Court's decision."
About Cetylated Fatty Acids or CFA's -
Cetylated Fatty Acids or CFA's are rooted in a health compound(s) derived through a process of "esterifying" fatty acids. The origin of CFA's can be traced to discoveries made and processes developed by Dr. Harry W. Diehl, Ph.D., including Cetyl Myristoleate or the cetyl ester of Myristoleic Acid. CFA's are all-natural and have been clinically demonstrated to help support, and indeed restore joint health and flexibility. CFA's are marketed under various brand names, including CetylMax(R) and Flexadren(R). There have been many studies performed on and scientific presentations made relating to CFA's. Published scholarly articles have described the systemic enhancement and lubricating properties of CFA's to cell membranes throughout the body, providing youthful cell fluidity and elasticity. Some of the benefits of CFA's include the enhancement of joint fluids that cushion bones and joints ¿ to maintain flexibility and mobility, so that an individual can move with greater ease and range-of-motion. CFA's have been proven to provide cumulative (continuous and restorative) benefits.
About CetylMax(R) and Flexadren(R) --
CetylMax(R) and Flexadren(R) product lines consist of both tablet form and topical over-the-counter (OTC) joint support supplements (also known as nutraceuticals) available directly to consumers through the Internet at www.cetylmax.com and www.flexadren.com. Both products are manufactured under FDA guidelines using the highest quality formulations of Cetylated Fatty Acids or CFA's and Glucosamine. Among other positive benefits, CetylMax(R) and Flexadren(R) aid in restoring soft tissue within and lubrication of joints throughout the body, which helps ease inflammation and the pain caused by inflammation.*
CetylMax(R) and Flexadren(R) are part of the Optimal Health Science(R) www.optimalhealthscience.com family of anti-aging products.
* These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
|SOURCE Optimal Health Science|
Copyright©2009 PR Newswire.
All rights reserved